ArticleFrontiers in pharmacology2025
Population pharmacokinetic modeling of dexmedetomidine nasal spray in Chinese adults.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intranasal Dexmedetomidine Combined with Local Infiltration Anesthesia for Perioperative Pain and Anxiety in PELD: A Retrospective Cohort Study.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The main objective was to build and qualify a population pharmacokinetic (PopPK) model for dexmedetomidine nasal spray in Chinese adults and explore the covariates affecting the PopPK model parameters. Methods: A population pharmacokinetic model was developed based on the results of 1,225 blood concentration points from 196 healthy volunteers (HV) and patients in phase I and phase III studies. Covariates significantly affecting pharmacokinetic characteristics were analyzed. Model selection was performed using nonlinear mixed-effects modeling (NONMEM), and covariates' screening was conducted using the traditional stepwise forward inclusion and backward elimination methods. Bootstrap and pcVPC methods were used for model validation. Logistic regression modeling was used to analyze the relationship between the C Results: The final model was a two-compartment model with first-order absorption and linear elimination. Inter-individual variability terms were estimated on clearance and absorption rate constant. The residual variability was described using combined proportional and additive error models. In the final model, body weight was included via theory-based allometric scaling (i.e., exponents of 0.75 for clearances and 1.0 for volumes of distribution). The absorption rate in the patients from phase III study was approximately 49% of that in the HV from phase I study. The estimated population typical values for CL, V2, Q, Vp, KA, F1, and ALAG in the final model were 35.3 L/h, 21.5 L, 116 L/h, 86.5 L, 0.523 h Conclusion: The present analysis successfully established a PopPK model for dexmedetomidine nasal spray in Chinese adults, confirming that body weight influences distribution and clearance. This PopPK model is being further explored to support pediatric dose recommendation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.